We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Diagnostic Assay Will Be Developed to Detect Aspergillus

By LabMedica International staff writers
Posted on 10 Aug 2011
A molecular diagnostic assay will be developed to detect the life-threatening Aspergillus fungus in human blood.

BD Diagnostics (Baltimore, MD, USA) a segment of global medical technology company Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA) and Lab21(Cambridge, United Kingdom) a global leader in personalized healthcare, will collaborate to develop the Aspergillus assay using the new fully automated BD MAX molecular testing system.

Infection caused by Aspergillus is a leading cause of death in immunocompromised patients, with an estimated 10 million people at risk globally each year. More...
Diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90% to 40%–highlighting the need for rapid, accurate testing. Real-time polymerase chain reaction may offer significant advantages in sensitivity and specificity over the current culture techniques

"The potential to detect Aspergillus in blood using real-time polymerase chain reaction is a topic of great interest to clinicians since it offers faster, more sensitive, and more accurate diagnostic and screening strategies for the early and definitive detection of aspergillosis,” said Graham Mullis, CEO of Lab21.

BD plans to bring new assays to the BD MAX System in a broad range of disease categories. There are now more than 14 assays in the BD MAX system’s menu pipeline. Combined with open capability, full automation, and standardized workflow, BD MAX system will enable laboratories to consolidate and standardize their molecular tests to build programs that meet both their current and future clinical needs.

Related Links:

BD Diagnostics
Becton, Dickinson and Company
Lab2



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.